Pfizer, Allergan deal dead, what could be next?

Pfizer Allergan Merger

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!